Transforming the Treatment of Neuromuscular Diseases
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
Creating the new generation of genetic therapies
Advancing revolutionary therapies to treat degenerative neuromuscular diseases
Careers at PepGen
We’re seeking passionate individuals who can help us to create therapies to improve the future of people living with neuromuscular diseases
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results CallRead Press Release
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific ConferenceRead Press Release
Sorry, we couldn't find any posts. Please try a different search.